Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
BRUSSELS , Nov. 8, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced important new rheumatology data being presented on CIMZIA ® (certolizumab pegol) and investigational molecules bimekizumab and dapirolizumab pegol at the 2019 American College of Rheumat...
BRUSSELS and THOUSAND OAKS, California , Oct. 18, 2019 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), ...
THOUSAND OAKS, Calif. and BRUSSELS , Oct. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ad...
BRUSSELS , Oct. 17, 2019 /PRNewswire/ -- Regulated Information - Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of three Phase 3 studies evaluating the efficacy and safety of bimekizumab, an IL-17A and IL-17F inhib...
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab , an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline;...
- Osteoporosis is estimated to affect 200 million people worldwide 1 and results in a fracture every 3 seconds 2 yet a new survey reveals bone specialists in Europe think its impact is not fully recognised 3 - Specialists (82%) believe osteoporosis is a silent...
BRUSSELS , July 25, 2019 /PRNewswire/ -- – Regulated information – Revenue reached € 2.3 billion (+2%, +4% CER 1 ) net sales increased to € 2.2 billion (+3%, +5% CER – adjusted 2 +11%, +7% CER) Underlying profitability (rEBITDA 3 ) was ...
Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...
THOUSAND OAKS, Calif. and BRUSSELS , June 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...
BRUSSELS , June 14, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced new Phase 2b data on the company's key pipeline molecule, bimekizumab – a novel humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F ...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price! PR Newswire Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the fu...
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...